OPRM1 and constipation disorder: In contrast to these general approaches, which may help to alleviate the end result of gastrointestinal mu-opioid receptor stimulation, peripherally acting mu-opioid receptor antagonists (PAMORAs) were designed specifically to target the molecular mechanism underlying the development of constipation caused by an opioid.